- Pot May Not Be the Best Rx for a Migraine
- Study Debunks Notion That Statin Meds Trigger Muscle Aches
- Stem Cell Injections Show Early Promise Against Spinal Cord Injuries
- Many Women Getting Wrong Antibiotics to Treat a UTI: Study
- AHA News: Which Blood Pressure Number Matters Most Might Depend on Your Age
- AHA News: Finally Getting Around to That Annual Physical? Here’s What You Might Find
- Sharp Drop Seen in COVID Testing As New Cases Plateau
- Health Highlights, March 1, 2021
- Pandemic Unemployment Has Taken Its Own Deadly Toll
- If Protections Expire, COVID Patients Could Soon Face Big Medical Bills
Replacement Therapy Approved for Gaucher Disease
FRIDAY, Feb. 26Velaglucerase alfa for injection (VPRIV) has been approved by the U.S. Food and Drug Administration to treat a rare inherited disorder called Gaucher disease, the agency said Friday.
The disorder is caused by lack of an enzyme called glucocerebrosidase. This allows a fatty substance called a lipid to build up in the liver, spleen, bones, bone marrow and nervous system. The disorder affects only about 1 in 50,000 people, the FDA said in a news release.
The newly approved treatment replaces the lacking enzyme in people with Type 1 Gaucher disease, the disorder’s most common form. An older form of replacement therapy is in short supply, the agency said.
VPRIV’s safety and effectiveness were evaluated in clinical trials involving 82 people aged 4 and older with Type 1 Gaucher. The most common side effects reported were allergic reactions; dizziness; pain in the abdomen, joints and back; nausea, fatigue, fever, and prolonged blood clotting.
VPRIV is produced by Massachusetts-based Shire Human Genetic Therapies Inc.
More information
The U.S. National Institute of Neurological Disorders and Stroke has more about this disorder.
Source: HealthDay
